Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

STAT-C Agents In Development For Hepatitis C

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

STAT-C Agents In Development For Hepatitis C



Class

Phase III

Phase II

Phase I

Interferons

Novartis/HGSI'sAlbuferon

Biolex's locteron

Protease Inhibitors

Vertex's telapravir

Schering-Plough's bocepravir

J&J/Medivir's TMC435350

Roche/InterMune ITMN-191/R7227

Merck's MK-7009

Boehringer Inghelheim's BI201335

Polymerase Inhibitors

Roche/Pharmasset's R7128

Gilead's GS 9190

Vertex/ViroChem's VCH 759

Bristol-Myers Squibb's BMS 650032

Pfizer's PF 00868554

Anadys' ANA598

Idenix's IDX 184

Vertex/ViroChem's VCH 222

Merck's MK-3281

NS5A Inhibitor

Bristol-Myers Squibb's BMS 790052

Caspase Inhibitor

Gilead's GS 9450

Tarmogen

GlobeImmune's GI-5005

Cyclophilin Inhibitors

DebioPharm's Debio 025

Scynexis' SCY-635

Sources: Sanford C. Bernstein Research; The Pink Sheet
Note: Chart does not include preclinical programs, and excludes BMS 791325, a STAT-C of unknown category in Phase I, and MK-0608, a Merck/Isis-partnered polymerase inhibitor for which development reportedly has ended.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS004151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By